115 related articles for article (PubMed ID: 26267322)
1. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Singha B; Gatla HR; Manna S; Chang TP; Sanacora S; Poltoratsky V; Vancura A; Vancurova I
J Biol Chem; 2014 Jan; 289(5):2687-700. PubMed ID: 24337575
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
Manna S; Singha B; Phyo SA; Gatla HR; Chang TP; Sanacora S; Ramaswami S; Vancurova I
J Immunol; 2013 Sep; 191(5):2837-46. PubMed ID: 23894194
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S; Ohmichi M; Nishio Y; Hayasaka T; Kimura A; Ohta T; Kawagoe J; Takahashi K; Yada-Hashimoto N; Seino-Noda H; Sakata M; Motoyama T; Kurachi H; Testa JR; Tasaka K; Murata Y
Clin Cancer Res; 2004 Nov; 10(22):7645-54. PubMed ID: 15569997
[TBL] [Abstract][Full Text] [Related]
7. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells.
Uddin MM; Gaire B; Deza B; Vancurova I
Methods Mol Biol; 2020; 2108():107-115. PubMed ID: 31939174
[TBL] [Abstract][Full Text] [Related]
9. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapies Targeting HDAC and IKK in Solid Tumors.
Vancurova I; Uddin MM; Zou Y; Vancura A
Trends Pharmacol Sci; 2018 Mar; 39(3):295-306. PubMed ID: 29233541
[TBL] [Abstract][Full Text] [Related]
13. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
14. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
15. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
17. Anticancer drug bortezomib increases interleukin-8 expression in human monocytes.
Sanacora S; Urdinez J; Chang TP; Vancurova I
Biochem Biophys Res Commun; 2015 May; 460(2):375-9. PubMed ID: 25791477
[TBL] [Abstract][Full Text] [Related]
18. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
19. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
20. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]